Home
#Global Trends
#Vietnam
#M&A
#Regulations
#Knowledge
#Events

Category: Uncategorized

Targeted Thoracic Oncology: AstraZeneca and Hutchmed Report Statistically Significant Progression-Free Survival Benefit in Phase 3 Trial Evaluating First-Line Tagrisso® (Osimertinib) Plus Orpathys® (Savolitinib) in EGFRm / MET+ Advanced NSCLC

03/09/2026 Published by Pharma Biz

Key Development On September 1, 2026, biopharmaceutical multinational AstraZeneca (LSE: AZN / Nasdaq: AZN) and its partner Hutchmed (China) Limited... Read more

Tags: #Global Trends

Consumer Health Antitrust Clearance: Australian Competition and Consumer Commission (ACCC) Approves Kimberly-Clark’s $40 Billion Takeover of Kenvue Conditioned on Divestment of Carefree® and Stayfree® Period Care Brands

03/09/2026 Published by Pharma Biz

Key Development On September 2, 2026, the Australian Competition and Consumer Commission (ACCC) granted conditional antitrust clearance for the proposed... Read more

Category: Uncategorized

Tags: #M&A

Pediatric Nutrition Litigation & Product Liability Defense: U.S. Federal Bellwether Jury Delivers Complete Defense Verdict for Mead Johnson (Reckitt) Over Enfamil – Rejecting Causation Claims in Preterm Necrotizing Enterocolitis (NEC)

03/09/2026 Published by Pharma Biz

Key Development On September 1, 2026, a federal jury in Illinois returned a complete defense verdict in favor of Mead... Read more

Category: Uncategorized

Tags: #Global Trends

Hematologic Oncology & Next-Gen Multispecifics: Roche Inks Potential $1.53 Billion Global Licensing Agreement for Simcere Zaiming’s Preclinical Trispecific T-Cell Engager SIM0660 (CD79a × CD19 × CD3) Targeting Relapsed B-Cell Malignancies and Autoimmune Disorders

03/09/2026 Published by Pharma Biz

Key Development On September 1, 2026, Swiss healthcare conglomerate Roche Holding AG (SIX: RO / ROPC) entered into an exclusive... Read more

Category: Uncategorized

Tags: #Global Trends

Agricultural Life Sciences & Global Agrifood Resilience: Bayer Launches First 2 of 10 Projected €500M+ Blockbusters – Advancing Plenexos® Insecticide and Preceon® Smart Corn System Alongside €400M in Operational Cost Savings

03/09/2026 Published by Pharma Biz

Key Development On September 2, 2026, during an institutional investor symposium convened in Iowa, German life sciences conglomerate Bayer AG... Read more

Category: Uncategorized

Tags: #Global Trends

Biopharmaceutical Formulation & Drug Delivery Innovation: Novartis Secures Multi-Target Global Licensing Deal Worth Up to $3.22 Billion for Alteogen’s Hybrozyme™ (ALT-B4) Platform – Enabling Subcutaneous Delivery for Core Biologics

03/09/2026 Published by Pharma Biz

On September 2, 2026, South Korean biopharmaceutical platform developer Alteogen Inc. (KOSDAQ: 196170) announced a major multi-target global licensing agreement... Read more

Category: Uncategorized

Tags: #M&A

AI-Driven Drug Discovery & Computational Oncology: Boehringer Ingelheim Licenses Owkin’s ‘K Pro’ AI Engine and Multimodal Biological Datasets to Accelerate Target Identification in Cancer and Immunology

03/09/2026 Published by Pharma Biz

Key Development On September 2, 2026, biomedical artificial intelligence innovator Owkin, Inc. entered into a strategic licensing and research partnership... Read more

Category: Uncategorized

Tags: #Global Trends

Biopharmaceutical Manufacturing Recovery & Incretin Strategy: Aspen Pharmacare Projects FY27 Normalized EBITDA of at Least 9 Billion Rand ($561 Million) – Accelerating Generic Semaglutide Expansion Across Emerging Markets Alongside Exclusive Mounjaro Commercialization

03/09/2026 Published by Pharma Biz

Key Development On September 2, 2026, South Africa-based pharmaceutical leader Aspen Pharmacare Holdings Ltd. (JSE: APN) issued financial guidance for... Read more

Category: Uncategorized

Tags: #Global Trends